These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21255545)

  • 1. Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus.
    Garces G; Contreras G; Carvalho D; Jaraba IM; Carvalho C; Tzakis A; Moon J; Ratnam K; Roth D
    Clin Nephrol; 2011 Feb; 75(2):150-7. PubMed ID: 21255545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of chronic kidney disease progression used by calcineurin inhibitor concentration and estimated glomerular filtration rate early after liver transplantation.
    Ye L; Zhang Y; Tang H; Yao J; Wang G; Yang Y; Chen G
    Niger J Clin Pract; 2020 Oct; 23(10):1387-1394. PubMed ID: 33047695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up.
    LaMattina JC; Mezrich JD; Fernandez LA; D'Alessandro AM; Djamali A; Musat AI; Pirsch JD; Foley DP
    Clin Transplant; 2013; 27(2):193-202. PubMed ID: 23294013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic kidney disease following liver transplantation: a South Australian experience.
    Ramachandran J; Juneja R; John L; Dutta AK; Chen JW; Woodman RJ; Wigg AJ
    Transplant Proc; 2010 Nov; 42(9):3644-6. PubMed ID: 21094832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.
    Hao JC; Wang WT; Yan LN; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
    World J Gastroenterol; 2014 Aug; 20(32):11356-62. PubMed ID: 25170222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation.
    Maurel P; Prémaud A; Carrier P; Essig M; Barbier L; Rousseau A; Silvain C; Causse X; Debette-Gratien M; Jacques J; Marquet P; Salamé E; Loustaud-Ratti V
    Transplantation; 2021 Jul; 105(7):1585-1594. PubMed ID: 32639405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End-stage renal disease after liver transplantation in patients with pre-transplant chronic kidney disease.
    Bahirwani R; Forde KA; Mu Y; Lin F; Reese P; Goldberg D; Abt P; Reddy KR; Levine M
    Clin Transplant; 2014 Feb; 28(2):205-10. PubMed ID: 24382253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease stage progression in liver transplant recipients.
    Lamattina JC; Foley DP; Mezrich JD; Fernandez LA; Vidyasagar V; D'Alessandro AM; Musat AI; Samaniego-Picota MD; Pascual J; Alejandro MD; Leverson GE; Pirsch JD; Djamali A
    Clin J Am Soc Nephrol; 2011 Aug; 6(8):1851-7. PubMed ID: 21784823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of long-term exposure to tacrolimus on chronic kidney disease after lung transplantation: A retrospective analysis from a single transplantation center.
    Xiong D; Yue B; Ye S; Wang H; Ban L; Chen Y; Lv J; Zhou M; Yin P; Chen J
    Transpl Immunol; 2023 Jun; 78():101810. PubMed ID: 36918103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.
    Chapman WC; Brown RS; Chavin KD; Sudan D; Koneru B; Junge G; Dong G; Patel D; Teperman L; Fung JJ
    Transplantation; 2017 Feb; 101(2):341-349. PubMed ID: 28121741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health multi-site study.
    Bahirwani R; Barin B; Olthoff K; Stock P; Murphy B; Rajender Reddy K;
    Liver Transpl; 2013 Jun; 19(6):619-26. PubMed ID: 23512786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of chronic kidney disease after orthotopic liver transplantation in a Chinese cohort.
    Peng JC; Li YJ; Wang J-; Zhu ML; Gao Y
    Clin Exp Nephrol; 2020 Sep; 24(9):806-812. PubMed ID: 32504202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal outcomes after liver transplantation in the model for end-stage liver disease era.
    Sharma P; Welch K; Eikstadt R; Marrero JA; Fontana RJ; Lok AS
    Liver Transpl; 2009 Sep; 15(9):1142-8. PubMed ID: 19718633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in patients with chronic kidney disease: a 5-year retrospective cohort study at a University Hospital in Japan.
    Yamashita T; Yoshida T; Ogawa T; Tsuchiya K; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):831-40. PubMed ID: 21800234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low estimated glomerular filtration rate and chronic kidney failure following liver transplant: a retrospective cohort study.
    Narciso RC; Ferraz LR; Rodrigues CJ; Monte JC; Mie S; Dos Santos OF; Paes ÂT; Cendoroglo M; Jaber BL; Durão MS; Batista MC
    Int J Artif Organs; 2013 Jul; 36(7):498-505. PubMed ID: 23897230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.